Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer — from feasibility to precision practice

Study limitation reported by the research below: “HER2-low metastatic breast cancer is discussed as a subgroup of interest but no outcome data specific to this population are presented.”